IP Library Granted Patent US 11,597,912
Granted Patent B2
US 11,597,912 · App. 17/709,979 · Granted Mar 7, 2023

Method of producing regulatory T cells by culturing regulatory T cells obtained from umbilical cord blood

Inventors: Yong Chan Kim (Gaithersburg, MD); Nari Byun (Gaithersburg, MD); Jeong Heon Yoon (Gaithersburg, MD)
Assignee: TERAIMMUNE, INC.
C12N5/0637A61K35/17A61P37/06C12N2500/40C12N2501/04C12N2501/15C12N2501/2302
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,597,912
App. No.
17/709,979
Granted
Mar 7, 2023
Kind
B2
Abstract

The present disclosure provides a method for producing a population of regulatory T cells comprising culturing an initial population of regulatory T cells obtained from umbilical cord blood in a media comprising an oligonucleotide having the sequence of AATCGTAACCGTCGTATCGGCGAT (SEQ ID NO: 1) to expand the initial population of regulatory T cells, and a method of treating an autoimmune disease comprising administering to a subject in need thereof an effective amount of a composition comprising the regulatory T cells prepared by the above method.

Claims (6)

1. A method for producing a population of regulatory T cells comprising:

culturing an initial population of regulatory T cells obtained from umbilical cord blood in a media comprising an oligonucleotide of SEQ ID NO. 1 to expand the initial population of regulatory T cells.

2. The method of claim 1 , wherein the media further comprises TGFβ1.

3. The method of claim 1 , wherein the media further comprises rapamycin.

4. The method of claim 1 , wherein the media further comprises TGFβ1 and rapamycin.

5. The method of claim 1 , wherein the initial population of regulatory T cells has been enriched for CD4 + CD25 +/hi CD127 lo/− FoxP3 + .

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 064450 FRAME: 0948. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 12, 2023
From: BOUNCE MERGER SUB II, LLC
To: TERAIMMUNE, LLC
Reel/Frame 065220/0567 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE SHOULD BE CHANGE OF NAME (NOT MERGER AND CHANGE OF NAME) AND ASSIGNEE NAME SHOULD BE TERAIMMUNE, LLC PREVIOUSLY RECORDED AT REEL: 064450 FRAME: 0947. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Sep 22, 2023
From: BOUNCE MERGER SUB II, LLC
To: TERAIMMUNE, LLC
Reel/Frame 065218/0503 →
MERGER AND CHANGE OF NAME Recorded Aug 1, 2023
From: BOUNCE MERGER SUB II, LLC; TERAIMMUNE, INC.
To: TERRAIMMUNE, LLC
Reel/Frame 064450/0947 →
MERGER Recorded Jul 20, 2023
From: TERAIMMUNE, INC.
To: BOUNCE MERGER SUB II, LLC
Reel/Frame 064331/0743 →
SECURITY INTEREST Recorded Jul 18, 2023
From: BOUNCE MERGER SUB II, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 064298/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2022
From: KIM, YONG CHAN; BYUN, NARI; YOON, JEONG HEON
To: TERAIMMUNE, INC.
Reel/Frame 059461/0127 →
Continuity (2)
Provisional Application 63170214 · Apr 2, 2021
Related Publication 20220325243A1 · Oct 13, 2022